Zusammenfassung
Das polyzystische Ovarsyndrom (PCOS) ist eine der häufigsten Ursachen für die weibliche
Infertilität. Neben den typischen Symptomen wie Oligo-/Amenorrhö, Hyperandrogenämie
und Adipositas werden auch periphere Insulinresistenz, gestörte Glukosetoleranz und
Hyperlipidämie beobachtet. Die Hyperinsulinämie und Veränderungen im IGF/IGFBP-System
(insulin-like growth factor/insulin-like growth factor binding protein) spielen in der Pathogenese des PCOS vermutlich eine wichtige Rolle. Insulin
und IGF bewirken eine Stimulation der ovariellen Androgenproduktion.
Vor diesem pathogenetischen Hintergrund erscheint eine Behandlung des PCOS durch Verbesserung
der metabolischen Situation durch orale Antidiabetika wie z. B. Metformin sinnvoll:
Metformin erhöht die Insulinempfindlichkeit, reduziert aber auch die Glukoseaufnahme
aus dem Darm und ebenso die hepatische Glukoneogenese. Beim PCOS bewirkt Metformin
eine Zyklusregulierung mit deutlicher Steigerung der Ovulationsrate sowie eine Gewichtsreduktion
bei meistens adipösen PCOS-Patientinnen. Des Weiteren kommt es unter der Therapie
zu einer Reduktion des Testosteronspiegels und Besserung der Akne sowie des Hirsutismus.
Im Rahmen der Sterilitätstherapie zeigt sich ein besseres Ansprechen auf die Clomiphen-
und FSH-Stimulation mit einer Erhöhung der Schwangerschaftsraten. Erste Studien zeigen
auch einen positiven Effekt in der Frühschwangerschaft mit einer Reduktion der Fehlgeburtenrate,
wobei es hier noch weiterer Untersuchungen bedarf. Die Metformineinnahme sollte in
der Therapie des PCOS über mindestens 3 Monate erfolgen. Die Dosierung beträgt 3 ×
500 mg, bzw. 2 × 850 mg. Prinzipiell ist die Metformintherapie bei adipösen PCOS-Patientinnen
mit abdominalem Fettverteilungsmuster und peripherer Insulinresistenz indiziert, wobei
auch die schlanken PCOS-Patientinnen von der Therapie profitieren können.
Abstract
The polycystic ovary syndrome (PCOS) is a common reason for female subfertility. Apart
from the cardinal symptoms of irregular menstrual bleeding, hyperandrogenism and obesity,
many women with PCOS have insulin resistance, impaired glucose tolerance and hyperlipidemia.
Hyperinsulinemia and changes in insulin-like growth factor (IGF) and its binding protein
appear to be central in the pathogenesis of PCOS. Both insulin and IGF indirectly
stimulate ovarian synthesis of androgens. This suggests using antidiabetic agents
to treat women with PCOS. Metformin increases insulin sensitivity, reduces glucose
uptake and inhibits hepatic glucose synthesis. In obese women metformin promotes weight
loss, improves menstrual control and increases ovuation rates. With metformin treatment,
testosterone levels decrease and acne and hirsism improve. For ovarian stimulation,
metformin improves the response to clomiphene or FSH, with increased pregancy rates.
Some studies suggest reduced rates of pregnancy loss with metformin in early pregnancy.
Metformin seems appropriate particularly for obese PCOS patients with peripheral insulin
resistance. The recommended dosage is 500 mg tid or 850 mg bid for at least 3 months.
Schlüsselwörter
PCOS - Hyperandrogenämie - IGF - Hyperinsulinämie - Metformin - Sterilitätstherapie
Key words
PCOS - hyperandrogenemia - IGF - hyperinsulinemia - metformin infertility
Literatur
- 1
Adams J. et al .
Multifollicular ovaries: clinical and endocrine features and response to pulsatile
gonadotropin releasing hormone.
Lancet.
1985;
2
1375-1379
- 2
Azziz R. et al .
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a
multicenter, double blind, placebo-controlled trial.
J Clin Endocrinol Metab.
2001;
86
1626-1632
- 3 Balen A.
. Homburg R (ed) Polycystic Ovary Syndrome. Martin Dunitz 2001: 19-27
- 4
Barbieri R L. et al .
The role of hyperinsulinemia in pathogenesis of ovarian hyperandrogenism.
Fertil Steril.
1988;
50
197-212
- 5
Barbieri R L.
Induction of ovulation in infertile women with hyperandrogenism and insulin resistance.
Am J Obstet Gynecol.
2000;
183
412-1418
- 6
Burghen G A. et al .
Correlation of hyperandrogenism with hyperinsulinism in polycystic ovary disease.
J Clin Endocrinol Metab.
1980;
50
113-116
- 7
Clark A M. et al .
Weight loss in obese infertile women results in improvement in reproductive outcome
for all forms of fertility treatment.
Hum Reprod.
1988;
13
1502-1505
- 8
Coetzee E J, Jackson W P.
Oral hypoglycaemics in the first trimester and fetal outcome.
S Afr Med J.
1984;
65
635-637
- 9
De Leo. et al .
Effects of metformin on gonadotropin-induces ovulation in women with polycystic ovary
syndrome.
Fertil Steril.
1999;
72
282-285
- 10
De Leo. et al .
Effect of metformin on insulin-like growth factor (IGF) 1 and IGF-binding protein
1 in polycystic ovary syndrome.
J Clin Endocrinol Metab.
2000;
85
1598-1600
- 11
Diamanti-Kandarakis E. et al .
Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic
ovary syndrome.
Eur J Endocrinol.
1998;
138
269-274
- 12
Dunaif A. et al .
Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary
syndrome.
Diabetes.
1992;
41
1257-1266
- 13
Dunaif A. et al .
Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal
muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome.
J Clin Invest.
1995;
96
801-810
- 14 Dunaif A. et al .Polycystic Ovary Syndrom (Current Issues in Endocrinology and
Metabolism). 1st ed. Boston; Blackwell Scientific 1992
- 15
Dunaif A. et al .
β-cell dysfunction independent of obesity and glucose intolerance in the polycystic
ovary syndrome.
J Clin Endocrinol Metab.
1996;
81
942-947
- 16
Ehrmann D A. et al .
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary
syndrome.
Diabetes Care.
1999;
22
141-146
- 17
Ehrmann D A. et al .
Effect of metformin on insulin secretion, insulin action and ovarian steroidogenesis
in women with polycystic ovary syndrome.
J Clin Endocrinol Metab.
1997;
82
524-530
- 18
Ehrmann D A. et al .
Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity
and familiy history of non-insulin-dependent diabetes mellitus.
J Clin Invest.
1995;
96
520-527
- 19
Fleming R. et al .
Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin
in randomized double-blind placebo-controlled trial.
J Clin Endocrinol Metab.
2002;
87
569-574
- 20
Geisthövel F.
Funktioneller Hyperandrogenismus (sog. „Syndrom polyzystischer Ovarien“).
Gynäkologe.
2002;
35
48-63
- 21
Gharani N. et al .
Association of the steroid synthesis gene CYP11a with polycystic ovary syndrom and
hyperandrogenism.
Hum Mol Genet.
1997;
6
397-402
- 22
Gjonnaess H.
Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome.
Fertil Steril.
1998;
69
697-701
- 23
Glueck C J. et al .
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome
appears to safely reduce first-trimester spontaneous abortion: a pilot study.
Fertil Steril.
2001;
75
46-52
- 24
Glueck C J. et al .
Metformin therapy throughout pregnancy reduces the development of gestational diabetes
in women with polycystic ovary syndrome.
Fertil Steril.
2002;
77
520-525
- 25
Glueck C J. et al .
Metformin-induced resumption of normal menses in 39 of 43 (91 %) previously amenorrheic
women with the polycystic ovary syndrome.
Metabolism.
1999;
48
511-519
- 26
Glueck C J. et al .
Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.
Hum Reprod.
2002;
17
2858-2864
- 27
Hasegawa I. et al .
Effect of troglitazone on endocrine and ovulatory performance in women with insulin
resistance-related polycystic ovary syndrome.
Fertil Steril.
1999;
71
323-327
- 28
Horton R. et al .
Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth
factor-1.
Endocrinol.
1993;
133
447-451
- 29
Jakubowicz D J. et al .
Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.
J Clin Endocrinol Metab.
2002;
87
524-529
- 30
Keck C, Geisthövel F.
Long-term FSH-Therapie zur Behandlung der Sterilität beim „hypersensitiven“ Ovar.
Geburtsh Frauenheilk.
1999;
59
215-219
- 31
Kocak M. et al .
Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in
clomiphene citrate-resistant women with polycystic ovary syndrome.
Fertil Steril.
2002;
77
101-106
- 32
Kolodziejczyk B. et al .
Metformin decreases hyperandrogenism and hyperinsulinemia in women with polycystic
ovary syndrome.
Fertil Steril.
2000;
73
1149-1154
- 33
La Marca A. et al .
Metformin treatment reduces ovarian cytochrome P-450 c17alpha response to human chorionic
gonadotropin in women with insulin resistance-related polycystic ovary syndrome.
Hum Reprod.
2000;
15
21-23
- 34
La Marca A. et al .
Effects of metformin an adrenal steroidgenesis in women with polycystic ovary syndrome.
Fertil Steril.
1999;
72
985-989
- 35
Legro R S. et al .
Prevalence and predictors of risk for Type 2 Diabetes mellitus and impaired glucose
tolerance in polycystic ovary syndrom: a prospective, controlled study in 254 affected
women.
J Clin Endocrinol Metab.
1999;
84
165-169
- 36
Legro R S, Strauss J F.
Molecular progress in infertility: polycystic ovary syndrom.
Fertil Steril.
2002;
78
569-576
- 37
Legro R S.
Polycystic ovary syndrom-long term sequelae and management.
Minerva Ginecologica.
2002;
54
97-114
- 38 Leidenberger F A. Klinische Endokrinologie für Frauenärzte. 2. Aufl. Springer-Verlag
1998
- 39
Mikola M. et al .
Obstetric outcome in women with polycystic ovarian syndrome.
Hum Reprod.
2001;
16
226-229
- 40
Moghetti P. et al .
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin
sensitivity in polycystic ovary syndrome: a randomised, double-blind, placebo-controlled
6-month trial, followed by open, long-term clinical evaluation.
J Clin Endocrin Metab.
2000;
85
139-146
- 41
Morin-Papunem L C. et al .
Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproteron acetate
in obese women with polycystic ovary syndrome: a randomized study.
J Clin Endocrin Metab.
2000;
85
3161-3168
- 42
Morin-Papunem L C. et al .
Metformin Therapy improves the menstrual pattern with minimal endocrine and metabolic
effects in women with polycystic ovary syndrome.
Fertil Steril.
1998;
69
691-696
- 43
Morin-Papunem L C. et al .
Decreased serum leptin concentration during metformin therapie in obese women with
polycystic ovary syndrome.
J Clin Endocrinol Metab.
1998;
83
2566-2568
- 44
Nardo L G. et al .
Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic
and reproductive effects.
Gynecol Endocrinol.
2001;
15
373-380
- 45
Nestler J E. et al .
Effects of metformin on spontaneus and clomiphen-induces ovulation in the polycystic
ovary syndrome.
New Eng J Med.
1998;
338
1876-1880
- 46
Nestler J E. et al .
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
N Engl J Med.
1999;
340
1314-1320
- 47
Nestler J E. et al .
Strategies for the use of insulin-sensitizing drugs to treat infertility in women
with polycystic ovary syndrome.
Fertil Steril.
2002;
77
209-215
- 48
Nestler J E.
Lean women with polycystic ovary syndrome respond to insulin reduction with decreases
in ovarian P450c17α activity and serum androgens.
J Clin Endocrinol Metab.
1997;
82
475-479
- 49
Nestler J E.
Letters to the Editor.
Fertil Steril.
2002;
78
654
- 50
Pasquali R. et al .
Effect of long-term treatment with metformin added to hypocaloric diet on body composition,
fat distribution, and androgen and insulin levels in abdominally obese women with
and without the polycystic ovary syndrome.
J Clin Endocrinol Metab.
2000;
85
2767-2774
- 51
Schweiger U. et al .
Das Syndrom der polyzystischen Ovarien.
Gynäkologe.
2002;
35
36-40
- 52
Seelig A S.
Intraovarielles Insulin-like Growth Faktor-System. Bedeutung beim polyzystischen Ovarsyndrom.
Gynäkologe.
2002;
35
41-47
- 53
Seli E, Duleba A J.
Should patients with polycystic ovary syndrome be treated with metformin? Proven and
potential benefits.
Hum Reprod.
2002;
17
2230-2236
- 54
Sills E S. et al .
Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic
ovary syndrome: a review of therapeutic rationale and reproductive outcomes.
Eur J Obst Gynecol.
2000;
91
135-141
- 55
Stadtmauer L A. et al .
Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro
fertilisation improves outcome and is associated with modulation of the insulin-like
growth factors.
Fertil Steril.
2001;
75
505-509
- 56
Urbanek M. et al .
Thirty-seven candidate genes for polycystic ovary syndrom: strongest evidence for
linkage is with follistatin.
Proc Natl Acad Sci USA.
1999;
96
8573-8578
- 57
Vandermolen D T. et al .
Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate
in patients with polycystic ovary syndrome who are resistant to clomiphene citarte
alone.
Fertil Steril.
2001;
75
310-315
- 58
Velasquez E M. et al .
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1,
lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic
ovary syndrome.
Metabolism.
1997;
46
454-457
- 59
Velazquez E M. et al .
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance,
hyperandrogenaemia, and systolic blood pressure while facilitating normal menses and
pregnancy.
Metab Clin Ep.
1994;
43
647-654
- 60
Waterworth D M. et al .
Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic
ovary syndrom.
Lancet.
1997;
349
986-990
- 61
Weiss J M. et al .
Das Karzinomrisiko von Frauen mit Syndrom der polyzystischen Ovarien (PCOS).
Gynäkologe.
2002;
35
31-35
- 62
Wild S. et al .
Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up:
a retrospective cohort study.
Clin Endocrinol.
2000;
52
595-600
- 63
Zhang L H. et al .
Serine phosphorylation of human P450c17 increases 17, 20-lyase activity: implications
for adrenarche and the polycystic ovary syndrome.
Proc Natl Acad Sci USA.
1995;
92
10619-10623
Dr. A. Hanjalic-Beck
Univ.-Frauenklinik Freiburg
Hugstetter Straße 55
79106 Freiburg
Email: hanjalic@frk.ukl.uni-freiburg.de